Concepts (203)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Experimental | 6 | 2021 | 131 | 2.270 |
Why?
|
| Nimodipine | 3 | 2023 | 3 | 2.120 |
Why?
|
| Dantrolene | 3 | 2023 | 3 | 1.530 |
Why?
|
| Vasospasm, Intracranial | 2 | 2021 | 14 | 1.320 |
Why?
|
| Cardiomyopathy, Dilated | 4 | 2012 | 30 | 1.250 |
Why?
|
| Cardiomyopathies | 4 | 2009 | 65 | 1.030 |
Why?
|
| Subarachnoid Hemorrhage | 2 | 2023 | 92 | 0.850 |
Why?
|
| Hemodynamics | 3 | 2011 | 100 | 0.690 |
Why?
|
| Angiotensin II | 4 | 2015 | 102 | 0.680 |
Why?
|
| Serotonin | 3 | 2021 | 123 | 0.630 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2014 | 89 | 0.610 |
Why?
|
| Rats | 11 | 2023 | 3735 | 0.580 |
Why?
|
| Heart | 2 | 2014 | 184 | 0.570 |
Why?
|
| Blood Glucose | 3 | 2015 | 389 | 0.560 |
Why?
|
| Propanolamines | 2 | 2008 | 13 | 0.550 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2008 | 54 | 0.540 |
Why?
|
| Cardiac Output | 7 | 2014 | 24 | 0.540 |
Why?
|
| Vasoconstriction | 3 | 2006 | 42 | 0.540 |
Why?
|
| Rats, Sprague-Dawley | 8 | 2023 | 1766 | 0.530 |
Why?
|
| Carbazoles | 2 | 2008 | 49 | 0.530 |
Why?
|
| Cricetinae | 8 | 2012 | 241 | 0.530 |
Why?
|
| Vasodilator Agents | 4 | 2019 | 55 | 0.520 |
Why?
|
| Animals | 21 | 2023 | 16992 | 0.510 |
Why?
|
| Heptanoic Acids | 2 | 2014 | 12 | 0.480 |
Why?
|
| Coronary Vessels | 3 | 2006 | 92 | 0.480 |
Why?
|
| Simvastatin | 2 | 2014 | 29 | 0.470 |
Why?
|
| Pyrroles | 2 | 2014 | 72 | 0.460 |
Why?
|
| Gastric Bypass | 1 | 2015 | 22 | 0.460 |
Why?
|
| Renin-Angiotensin System | 4 | 2013 | 48 | 0.450 |
Why?
|
| Celiac Artery | 1 | 2015 | 1 | 0.450 |
Why?
|
| Lipids | 2 | 2015 | 256 | 0.450 |
Why?
|
| Muscle, Smooth, Vascular | 4 | 2021 | 140 | 0.440 |
Why?
|
| Resistance Training | 1 | 2015 | 21 | 0.440 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 3 | 2012 | 41 | 0.430 |
Why?
|
| Endothelium, Vascular | 4 | 2019 | 263 | 0.420 |
Why?
|
| Toremifene | 2 | 2003 | 4 | 0.420 |
Why?
|
| Estrogen Antagonists | 2 | 2003 | 30 | 0.410 |
Why?
|
| Atrial Fibrillation | 2 | 2013 | 122 | 0.410 |
Why?
|
| Blood Pressure | 7 | 2015 | 666 | 0.410 |
Why?
|
| Ovariectomy | 2 | 2003 | 127 | 0.400 |
Why?
|
| Oxidative Stress | 2 | 2010 | 1003 | 0.400 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2014 | 92 | 0.390 |
Why?
|
| Hypertension | 3 | 2013 | 835 | 0.390 |
Why?
|
| Fumarates | 1 | 2012 | 11 | 0.370 |
Why?
|
| Male | 21 | 2021 | 23409 | 0.370 |
Why?
|
| Etomidate | 1 | 2011 | 1 | 0.360 |
Why?
|
| Mesocricetus | 5 | 2010 | 56 | 0.360 |
Why?
|
| Diabetes Complications | 2 | 2013 | 102 | 0.360 |
Why?
|
| Propofol | 1 | 2011 | 8 | 0.360 |
Why?
|
| Ketamine | 1 | 2011 | 13 | 0.360 |
Why?
|
| Puerto Rico | 7 | 2015 | 1413 | 0.360 |
Why?
|
| Amides | 1 | 2012 | 71 | 0.350 |
Why?
|
| Anesthetics | 1 | 2011 | 11 | 0.350 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2012 | 96 | 0.350 |
Why?
|
| Losartan | 2 | 2008 | 35 | 0.340 |
Why?
|
| Acetylcholine | 4 | 2019 | 77 | 0.340 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2008 | 78 | 0.330 |
Why?
|
| Disease Models, Animal | 7 | 2012 | 1596 | 0.330 |
Why?
|
| Aorta, Thoracic | 2 | 2010 | 31 | 0.330 |
Why?
|
| Acetylcysteine | 1 | 2010 | 57 | 0.330 |
Why?
|
| Coronary Circulation | 1 | 2009 | 29 | 0.310 |
Why?
|
| Antioxidants | 2 | 2010 | 443 | 0.300 |
Why?
|
| Heart Rate | 4 | 2014 | 266 | 0.300 |
Why?
|
| Potassium Chloride | 2 | 2006 | 24 | 0.300 |
Why?
|
| Exercise | 1 | 2015 | 692 | 0.290 |
Why?
|
| Enalapril | 1 | 2008 | 7 | 0.290 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2015 | 760 | 0.280 |
Why?
|
| Disease Progression | 5 | 2015 | 667 | 0.280 |
Why?
|
| Muscle Contraction | 3 | 2021 | 67 | 0.270 |
Why?
|
| Syncope | 1 | 2007 | 4 | 0.270 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2008 | 128 | 0.270 |
Why?
|
| Drug Therapy, Combination | 2 | 2021 | 234 | 0.250 |
Why?
|
| Streptozocin | 2 | 2021 | 26 | 0.240 |
Why?
|
| Vasoconstrictor Agents | 1 | 2006 | 39 | 0.240 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 749 | 0.240 |
Why?
|
| Time Factors | 4 | 2015 | 1857 | 0.230 |
Why?
|
| Ventricular Function, Left | 3 | 2014 | 114 | 0.230 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2019 | 1124 | 0.220 |
Why?
|
| Nitric Oxide | 2 | 2005 | 386 | 0.220 |
Why?
|
| Stroke Volume | 3 | 2011 | 122 | 0.210 |
Why?
|
| Doxorubicin | 1 | 2005 | 97 | 0.210 |
Why?
|
| Aging | 1 | 2009 | 783 | 0.210 |
Why?
|
| Blood Vessels | 1 | 2003 | 36 | 0.200 |
Why?
|
| Cardiovascular System | 1 | 2003 | 37 | 0.190 |
Why?
|
| Cerebrovascular Circulation | 1 | 2023 | 70 | 0.190 |
Why?
|
| Reactive Oxygen Species | 1 | 2005 | 532 | 0.190 |
Why?
|
| Insulin Resistance | 2 | 2015 | 201 | 0.180 |
Why?
|
| Muscle Relaxants, Central | 1 | 2021 | 5 | 0.180 |
Why?
|
| Humans | 14 | 2021 | 43102 | 0.170 |
Why?
|
| Calcium Channel Blockers | 1 | 2021 | 55 | 0.170 |
Why?
|
| Endothelin-1 | 2 | 2015 | 57 | 0.170 |
Why?
|
| Pravastatin | 2 | 2014 | 6 | 0.170 |
Why?
|
| Phenylephrine | 1 | 2019 | 34 | 0.160 |
Why?
|
| Echocardiography | 2 | 2010 | 167 | 0.130 |
Why?
|
| Peptidyl-Dipeptidase A | 2 | 2008 | 35 | 0.120 |
Why?
|
| Retrospective Studies | 3 | 2015 | 2544 | 0.120 |
Why?
|
| Nitric Oxide Synthase Type III | 2 | 2008 | 75 | 0.120 |
Why?
|
| Postoperative Period | 1 | 2015 | 33 | 0.120 |
Why?
|
| Swine | 2 | 2006 | 212 | 0.110 |
Why?
|
| Taurine | 1 | 2015 | 3 | 0.110 |
Why?
|
| Paullinia | 1 | 2015 | 3 | 0.110 |
Why?
|
| Caffeine | 1 | 2015 | 28 | 0.110 |
Why?
|
| Weight Loss | 1 | 2015 | 137 | 0.110 |
Why?
|
| Nitroprusside | 2 | 2003 | 14 | 0.100 |
Why?
|
| Isometric Contraction | 2 | 2003 | 25 | 0.100 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 153 | 0.100 |
Why?
|
| Norepinephrine | 2 | 2003 | 97 | 0.100 |
Why?
|
| Body Weight | 1 | 2015 | 429 | 0.100 |
Why?
|
| Heart Neoplasms | 1 | 2013 | 8 | 0.100 |
Why?
|
| Coronary Artery Disease | 1 | 2015 | 163 | 0.100 |
Why?
|
| Acid-Base Imbalance | 1 | 2013 | 3 | 0.100 |
Why?
|
| United States | 2 | 2015 | 5205 | 0.100 |
Why?
|
| Anti-Obesity Agents | 1 | 2013 | 11 | 0.100 |
Why?
|
| Critical Illness | 1 | 2013 | 47 | 0.090 |
Why?
|
| Diet, Mediterranean | 1 | 2013 | 37 | 0.090 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 173 | 0.090 |
Why?
|
| Magnesium | 1 | 2013 | 94 | 0.090 |
Why?
|
| Thiazolidinediones | 1 | 2013 | 49 | 0.090 |
Why?
|
| Valine | 1 | 2012 | 29 | 0.090 |
Why?
|
| Exercise Therapy | 1 | 2013 | 87 | 0.090 |
Why?
|
| Tetrazoles | 1 | 2012 | 46 | 0.090 |
Why?
|
| Incidence | 2 | 2013 | 1078 | 0.090 |
Why?
|
| Injections, Intraperitoneal | 1 | 2011 | 60 | 0.090 |
Why?
|
| Heart Diseases | 1 | 2013 | 112 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2015 | 925 | 0.080 |
Why?
|
| Middle Aged | 5 | 2015 | 12222 | 0.080 |
Why?
|
| Adult | 4 | 2015 | 13872 | 0.080 |
Why?
|
| Atherosclerosis | 1 | 2013 | 169 | 0.080 |
Why?
|
| Circadian Rhythm | 1 | 2013 | 236 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 734 | 0.070 |
Why?
|
| Cytokines | 1 | 2013 | 678 | 0.070 |
Why?
|
| Female | 6 | 2015 | 24698 | 0.070 |
Why?
|
| Acetamides | 1 | 2008 | 11 | 0.070 |
Why?
|
| Antiparkinson Agents | 1 | 2008 | 14 | 0.070 |
Why?
|
| Superoxides | 1 | 2008 | 57 | 0.070 |
Why?
|
| Ultrasonography | 1 | 2008 | 135 | 0.070 |
Why?
|
| Age Factors | 1 | 2010 | 1154 | 0.070 |
Why?
|
| Echocardiography, Doppler | 1 | 2007 | 41 | 0.070 |
Why?
|
| Inflammation | 1 | 2013 | 758 | 0.070 |
Why?
|
| Vasodilation | 1 | 2007 | 64 | 0.060 |
Why?
|
| Heart Failure | 1 | 2010 | 302 | 0.060 |
Why?
|
| Obesity | 1 | 2015 | 1151 | 0.060 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2006 | 5 | 0.060 |
Why?
|
| Pyrimidines | 1 | 2008 | 139 | 0.060 |
Why?
|
| Ketanserin | 1 | 2006 | 4 | 0.060 |
Why?
|
| Receptors, Serotonin, 5-HT1 | 1 | 2006 | 3 | 0.060 |
Why?
|
| Receptors, Serotonin, 5-HT2 | 1 | 2006 | 5 | 0.060 |
Why?
|
| Propranolol | 1 | 2006 | 18 | 0.060 |
Why?
|
| Receptor, Endothelin A | 1 | 2006 | 3 | 0.060 |
Why?
|
| Serotonin Antagonists | 1 | 2006 | 22 | 0.060 |
Why?
|
| Lovastatin | 1 | 2006 | 9 | 0.060 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2006 | 30 | 0.060 |
Why?
|
| Binding, Competitive | 1 | 2006 | 109 | 0.060 |
Why?
|
| Peptides, Cyclic | 1 | 2006 | 29 | 0.060 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2005 | 79 | 0.060 |
Why?
|
| Rats, Inbred SHR | 1 | 2005 | 30 | 0.060 |
Why?
|
| Systole | 1 | 2005 | 67 | 0.060 |
Why?
|
| Membrane Transport Proteins | 1 | 2005 | 100 | 0.050 |
Why?
|
| Models, Animal | 1 | 2005 | 151 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2005 | 201 | 0.050 |
Why?
|
| Risk Factors | 1 | 2013 | 3994 | 0.050 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2003 | 36 | 0.050 |
Why?
|
| Muscle Relaxation | 1 | 2003 | 19 | 0.050 |
Why?
|
| Hormones | 1 | 2003 | 55 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2005 | 206 | 0.050 |
Why?
|
| Aorta, Abdominal | 1 | 2003 | 17 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 259 | 0.050 |
Why?
|
| Nitric Oxide Synthase | 1 | 2003 | 135 | 0.050 |
Why?
|
| Aorta | 1 | 2003 | 198 | 0.050 |
Why?
|
| Myocardium | 1 | 2005 | 263 | 0.050 |
Why?
|
| Protein Binding | 1 | 2006 | 1082 | 0.050 |
Why?
|
| Estradiol | 1 | 2003 | 268 | 0.040 |
Why?
|
| Antihypertensive Agents | 1 | 2003 | 287 | 0.040 |
Why?
|
| Infant | 2 | 2013 | 1175 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2005 | 2157 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2013 | 1546 | 0.030 |
Why?
|
| Aged | 3 | 2013 | 8214 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2013 | 2853 | 0.020 |
Why?
|
| Hypokalemia | 1 | 2013 | 11 | 0.020 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2013 | 51 | 0.020 |
Why?
|
| Critical Care | 1 | 2013 | 49 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2013 | 72 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2013 | 185 | 0.020 |
Why?
|
| Child | 2 | 2013 | 3443 | 0.020 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2013 | 193 | 0.020 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2008 | 2 | 0.020 |
Why?
|
| Catalepsy | 1 | 2008 | 9 | 0.020 |
Why?
|
| Radioligand Assay | 1 | 2008 | 65 | 0.020 |
Why?
|
| Cricetulus | 1 | 2008 | 82 | 0.020 |
Why?
|
| Haloperidol | 1 | 2008 | 36 | 0.020 |
Why?
|
| Solubility | 1 | 2008 | 139 | 0.020 |
Why?
|
| Microsomes, Liver | 1 | 2008 | 75 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 2008 | 314 | 0.020 |
Why?
|
| Reaction Time | 1 | 2008 | 157 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2008 | 283 | 0.020 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2006 | 5 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2006 | 96 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2008 | 506 | 0.020 |
Why?
|
| Water | 1 | 2008 | 316 | 0.010 |
Why?
|
| Cell Line | 1 | 2008 | 1410 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2006 | 1604 | 0.010 |
Why?
|
| Young Adult | 1 | 2013 | 5080 | 0.010 |
Why?
|
| Adolescent | 1 | 2013 | 6081 | 0.010 |
Why?
|